6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Psoriatic	JJ	psoriatic	psoriatic	psoriat	N	O
Arthritis	NN	arthritis	arthritis	arthriti	Y	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Psoriasis	NN	psoriasis	psoriasis	psoriasi	Y	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
tension	NN	tension	tension	tension	Y	B-AdverseReaction
headache	NN	headache	headache	headach	Y	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Celgene	NNP	celgene	celgene	celgen	N	O
Corporation	NNP	corporation	corporation	corpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
423	CD	423	423	423	N	O
-	:	-	-	-	N	O
5436	CD	5436	5436	5436	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Psoriatic	JJ	psoriatic	psoriatic	psoriat	N	O
Arthritis	NNP	arthritis	arthritis	arthriti	Y	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNP	trials	trial	trial	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
[	JJ	[	[	[	N	O
Studies	NNPS	studies	study	studi	N	O
PsA	NNP	psa	psa	psa	Y	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
PsA	NNP	psa	psa	psa	Y	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
PsA	NNP	psa	psa	psa	Y	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
]	NN	]	]	]	N	O
of	IN	of	of	of	N	O
similar	JJ	similar	similar	similar	N	O
design	NN	design	design	design	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
psoriatic	JJ	psoriatic	psoriatic	psoriat	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
1493	CD	1493	1493	1493	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
equally	RB	equally	equally	equal	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
20	CD	20	20	20	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
or	CC	or	or	or	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Titration	NN	titration	titration	titrat	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
over	IN	over	over	over	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
5	CD	5	5	5	N	O
days	NNS	days	day	day	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
tender	NN	tender	tender	tender	N	O
and	CC	and	and	and	N	O
swollen	JJ	swollen	swollen	swollen	N	O
joint	NN	joint	joint	joint	N	O
counts	NNS	counts	count	count	N	O
had	VBD	had	had	had	N	O
not	RB	not	not	not	N	O
improved	VBN	improved	improved	improv	N	O
by	IN	by	by	by	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
20%	CD	20%	20%	20%	N	O
were	VBD	were	were	were	N	O
re	VBN	re	re	re	N	O
-	:	-	-	-	N	O
randomized	VBN	randomized	randomized	random	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
blinded	JJ	blinded	blinded	blind	N	O
fashion	NN	fashion	fashion	fashion	N	O
to	TO	to	to	to	N	O
either	DT	either	either	either	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
20	CD	20	20	20	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
or	CC	or	or	or	N	O
30	CD	30	30	30	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
at	IN	at	at	at	N	O
week	NN	week	week	week	N	O
16	CD	16	16	16	N	O
while	IN	while	while	while	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
patients	NNS	patients	patient	patient	N	O
remained	VBD	remained	remained	remain	N	O
on	IN	on	on	on	N	O
their	PRP$	their	their	their	N	O
initial	JJ	initial	initial	initi	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
ranged	VBD	ranged	ranged	rang	N	O
in	IN	in	in	in	N	O
age	NN	age	age	age	N	O
from	IN	from	from	from	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
83	CD	83	83	83	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
overall	JJ	overall	overall	overal	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
51	CD	51	51	51	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
presented	VBD	presented	presented	present	N	O
inTable	JJ	intable	intable	intabl	N	O
2	CD	2	2	2	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
tended	VBD	tended	tended	tend	N	O
to	TO	to	to	to	N	O
resolve	VB	resolve	resolve	resolv	N	O
over	IN	over	over	over	N	O
time	NN	time	time	time	N	O
with	IN	with	with	with	N	O
continued	JJ	continued	continued	continu	N	O
dosing	NN	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
were	VBD	were	were	were	N	O
nausea	RB	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
psoriatic	JJ	psoriatic	psoriatic	psoriat	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
any	DT	any	any	ani	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
4.6%	CD	4.6%	4.6%	4.6%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
and	CC	and	and	and	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
Twice	NNP	twice	twice	twice	N	O
Daily	NNP	daily	daily	daili	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
Than	NNP	than	than	than	N	O
That	WDT	that	that	that	N	O
Observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
for	IN	for	for	for	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
Day	NNP	day	day	day	N	O
112	CD	112	112	112	N	O
(	(	(	(	(	N	O
Week	NNP	week	week	week	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O

a	DT	a	a	a	N	O
Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reported	VBN	reported	reported	report	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
subject	NN	subject	subject	subject	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
and	CC	and	and	and	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
in	IN	in	in	in	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
;	:	;	;	;	N	O
1	CD	1	1	1	N	O
subject	NN	subject	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
20	CD	20	20	20	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
;	:	;	;	;	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reported	JJ	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
none	NN	none	none	none	N	O
were	VBD	were	were	were	N	O
serious	JJ	serious	serious	seriou	N	O
.	.	.	.	.	N	O

c	NNS	c	c	c	N	O
n	RB	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
indicates	VBZ	indicates	indicates	indic	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
percent	NN	percent	percent	percent	N	O
.	.	.	.	.	N	O

Placebo	NN	placebo	placebo	placebo	N	O

OTEZLA	$	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
BID	NN	bid	bid	bid	N	O

Preferred	JJ	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
Day	NNP	day	day	day	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
495	CD	495	495	495	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
c	VBP	c	c	c	N	O
Day	$	day	day	day	N	O
6	CD	6	6	6	N	O
to	TO	to	to	to	N	O
Day	NNP	day	day	day	N	O
112	CD	112	112	112	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
490	CD	490	490	490	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Day	VBZ	day	day	day	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
497	CD	497	497	497	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Day	VBZ	day	day	day	N	O
6	CD	6	6	6	N	O
to	TO	to	to	to	N	O
Day	NNP	day	day	day	N	O
112	CD	112	112	112	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
493	CD	493	493	493	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
a	DT	a	a	a	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
1.2	CD	1.2	1.2	1.2	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
1.6	CD	1.6	1.6	1.6	N	O
)	)	)	)	)	N	O
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
9.3	CD	9.3	9.3	9.3	N	O
)	)	)	)	)	N	O
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
7.7	CD	7.7	7.7	7.7	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
a	DT	a	a	a	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
3.1	CD	3.1	3.1	3.1	N	O
)	)	)	)	)	N	O
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
7.4	CD	7.4	7.4	7.4	N	O
)	)	)	)	)	N	O
44	CD	44	44	44	N	O
(	(	(	(	(	N	O
8.9	CD	8.9	8.9	8.9	N	O
)	)	)	)	)	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
a	DT	a	a	a	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
1.8	CD	1.8	1.8	1.8	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
4.8	CD	4.8	4.8	4.8	N	O
)	)	)	)	)	N	O
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tractinfection	NN	tractinfection	tractinfection	tractinfect	N	I-AdverseReaction
b	NN	b	b	b	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.6	CD	0.6	0.6	0.6	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
1.8	CD	1.8	1.8	1.8	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.6	CD	0.6	0.6	0.6	N	O
)	)	)	)	)	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
3.9	CD	3.9	3.9	3.9	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
a	DT	a	a	a	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.4	CD	0.4	0.4	0.4	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.4	CD	0.4	0.4	0.4	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.8	CD	0.8	0.8	0.8	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
3.2	CD	3.2	3.2	3.2	N	O
)	)	)	)	)	N	O

Nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
b	NN	b	b	b	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.2	CD	0.2	0.2	0.2	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
1.6	CD	1.6	1.6	1.6	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.2	CD	0.2	0.2	0.2	N	O
)	)	)	)	)	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
2.6	CD	2.6	2.6	2.6	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
b	NN	b	b	b	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0.0	CD	0.0	0.0	0.0	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.2	CD	0.2	0.2	0.2	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.6	CD	0.6	0.6	0.6	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
2.0	CD	2.0	2.0	2.0	N	O
)	)	)	)	)	N	O

Other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
including	VBG	including	including	includ	N	O
extension	NN	extension	extension	extens	N	O
studies	NNS	studies	study	studi	N	O
:	:	:	:	:	N	O
Immune	NNP	immune	immune	immun	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decrease	VBZ	decrease	decrease	decreas	N	I-AdverseReaction
Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Frequent	JJ	frequent	frequent	frequent	N	B-AdverseReaction
bowel	NN	bowel	bowel	bowel	N	I-AdverseReaction
movement	NN	movement	movement	movement	N	I-AdverseReaction
,	,	,	,	,	N	O
gastroesophageal	JJ	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	NN	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
dyspepsia	JJ	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
Metabolism	NNP	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NNP	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
Nervous	JJ	nervous	nervous	nervou	Y	O
System	NN	system	system	system	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Migraine	NNP	migraine	migraine	migrain	Y	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O

Psoriasis	NN	psoriasis	psoriasis	psoriasi	Y	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
1426	CD	1426	1426	1426	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
randomized	NNS	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
severe	VB	severe	severe	sever	N	O
plaque	JJ	plaque	plaque	plaqu	N	O
psoriasis	NN	psoriasis	psoriasis	psoriasi	Y	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
candidates	NNS	candidates	candidate	candid	N	O
for	IN	for	for	for	N	O
phototherapy	NN	phototherapy	phototherapy	phototherapi	Y	O
or	CC	or	or	or	N	O
systemic	JJ	systemic	systemic	system	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
or	CC	or	or	or	N	O
placebo	VB	placebo	placebo	placebo	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Titration	NN	titration	titration	titrat	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
over	IN	over	over	over	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
5	CD	5	5	5	N	O
days	NNS	days	day	day	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Subjects	NNS	subjects	subject	subject	N	O
ranged	VBD	ranged	ranged	rang	N	O
in	IN	in	in	in	N	O
age	NN	age	age	age	N	O
from	IN	from	from	from	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
83	CD	83	83	83	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
overall	JJ	overall	overall	overal	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
46	CD	46	46	46	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
taking	VBG	taking	taking	take	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
were	VBD	were	were	were	N	O
nausea	RB	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
psoriasis	NN	psoriasis	psoriasis	psoriasi	Y	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
any	DT	any	any	ani	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
6.1%	CD	6.1%	6.1%	6.1%	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
and	CC	and	and	and	N	O
4.1%	CD	4.1%	4.1%	4.1%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
on	IN	on	on	on	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
and	CC	and	and	and	N	O
With	IN	with	with	with	N	O
Greater	NNP	greater	greater	greater	N	O
Frequency	NNP	frequency	frequency	frequenc	N	O
Than	NNP	than	than	than	N	O
in	IN	in	in	in	N	O
Subjects	NNP	subjects	subject	subject	N	O
on	IN	on	on	on	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
;	:	;	;	;	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
Day	NNP	day	day	day	N	O
112	CD	112	112	112	N	O
(	(	(	(	(	N	O
Week	NNP	week	week	week	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O

Two	CD	two	two	two	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
experienced	VBD	experienced	experienced	experienc	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
.	.	.	.	.	N	O

Preferred	VBN	preferred	preferred	prefer	N	O

Term	NNP	term	term	term	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
506	CD	506	506	506	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
OTEZLA	VBP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NNS	mg	mg	mg	N	O
BID	NNP	bid	bid	bid	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
920	CD	920	920	920	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
32	CD	32	32	32	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
160	CD	160	160	160	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
35	CD	35	35	35	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
155	CD	155	155	155	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
31	CD	31	31	31	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
84	CD	84	84	84	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O

Tension	NNP	tension	tension	tension	Y	B-AdverseReaction
headache	NN	headache	headache	headach	Y	I-AdverseReaction
21	CD	21	21	21	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
75	CD	75	75	75	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
55	CD	55	55	55	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
35	CD	35	35	35	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Decrease	NNP	decrease	decrease	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
26	CD	26	26	26	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
21	CD	21	21	21	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Migraine	NN	migraine	migraine	migrain	Y	B-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Frequent	JJ	frequent	frequent	frequent	N	B-AdverseReaction
bowel	NN	bowel	bowel	bowel	N	I-AdverseReaction
movements	NNS	movements	movement	movement	N	I-AdverseReaction
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Depression	NN	depression	depression	depress	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Tooth	NNP	tooth	tooth	tooth	N	B-AdverseReaction
abscess	RB	abscess	abscess	abscess	Y	I-AdverseReaction
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Folliculitis	NN	folliculitis	folliculitis	follicul	Y	B-AdverseReaction
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Sinus	NNP	sinus	sinus	sinu	N	B-AdverseReaction
headache	NN	headache	headache	headach	Y	I-AdverseReaction
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Severe	JJ	severe	severe	sever	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
psoriasis	NN	psoriasis	psoriasis	psoriasi	Y	O
(	(	(	(	(	N	O
rebound	NN	rebound	rebound	rebound	N	O
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
1184	CD	1184	1184	1184	N	O
)	)	)	)	)	N	O
subjects	VBZ	subjects	subject	subject	N	O
following	VBG	following	following	follow	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Depression	NN	depression	depression	depress	Y	B-AdverseReaction
:	:	:	:	:	N	O
Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
their	PRP$	their	their	their	N	O
caregivers	NNS	caregivers	caregiver	caregiv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
families	NNS	families	family	famili	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
alert	JJ	alert	alert	alert	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
,	,	,	,	,	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
mood	NN	mood	mood	mood	N	O
changes	NNS	changes	change	chang	N	O
and	CC	and	and	and	N	O
if	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
changes	NNS	changes	change	chang	N	O
occur	VBP	occur	occur	occur	N	O
to	TO	to	to	to	N	O
contact	VB	contact	contact	contact	N	O
their	PRP$	their	their	their	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
.	.	.	.	.	N	O

Carefully	RB	carefully	carefully	care	N	O
weigh	JJ	weigh	weigh	weigh	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
suicidal	VB	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Weight	JJ	weight	weight	weight	Y	B-AdverseReaction
Decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
weight	VBD	weight	weight	weight	Y	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
unexplained	VBN	unexplained	unexplained	unexplain	N	O
or	CC	or	or	or	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
weight	JJ	weight	weight	weight	Y	O
loss	NN	loss	loss	loss	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
weight	JJ	weight	weight	weight	Y	O
loss	NN	loss	loss	loss	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Drug	NN	drug	drug	drug	N	O
Interactions	NNS	interactions	interaction	interact	N	O
:	:	:	:	:	N	O
Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
strong	JJ	strong	strong	strong	N	O
cytochrome	NN	cytochrome	cytochrome	cytochrom	N	O
P450	NNP	p450	p450	p450	N	O
enzyme	NN	enzyme	enzyme	enzym	N	O
inducers	NNS	inducers	inducer	induc	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
rifampin	NN	rifampin	rifampin	rifampin	N	O
,	,	,	,	,	N	O
phenobarbital	NN	phenobarbital	phenobarbital	phenobarbit	N	O
,	,	,	,	,	N	O
carbamazepine	NN	carbamazepine	carbamazepine	carbamazepin	N	O
,	,	,	,	,	N	O
phenytoin	NN	phenytoin	phenytoin	phenytoin	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
because	IN	because	because	becaus	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Depression	NN	depression	depression	depress	Y	O

Treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
is	VBZ	is	is	is	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
.	.	.	.	.	N	O

Before	IN	before	before	befor	N	O
using	VBG	using	using	use	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
suicidal	VB	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behavior	JJ	behavior	behavior	behavior	N	O
prescribers	NNS	prescribers	prescribers	prescrib	N	O
should	MD	should	should	should	N	O
carefully	RB	carefully	carefully	care	N	O
weigh	VB	weigh	weigh	weigh	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
in	IN	in	in	in	N	O
such	JJ	such	such	such	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
their	PRP$	their	their	their	N	O
caregivers	NNS	caregivers	caregiver	caregiv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
families	NNS	families	family	famili	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
need	NN	need	need	need	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
alert	JJ	alert	alert	alert	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
,	,	,	,	,	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
mood	NN	mood	mood	mood	N	O
changes	NNS	changes	change	chang	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
if	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
changes	NNS	changes	change	chang	N	O
occur	VBP	occur	occur	occur	N	O
to	TO	to	to	to	N	O
contact	VB	contact	contact	contact	N	O
their	PRP$	their	their	their	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
.	.	.	.	.	N	O

Prescribers	NNS	prescribers	prescribers	prescrib	N	O
should	MD	should	should	should	N	O
carefully	RB	carefully	carefully	care	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
continuing	VBG	continuing	continuing	continu	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
if	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
events	NNS	events	event	event	N	O
occur	VBP	occur	occur	occur	N	O
.	.	.	.	.	N	O

Psoriatic	JJ	psoriatic	psoriatic	psoriat	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
:	:	:	:	:	N	O
During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
0	CD	0	0	0	N	O
to	TO	to	to	to	N	O
16	CD	16	16	16	N	O
week	NN	week	week	week	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
998	CD	998	998	998	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
reported	VBD	reported	reported	report	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
or	CC	or	or	or	N	O
depressed	VBN	depressed	depressed	depress	N	B-AdverseReaction
mood	NN	mood	mood	mood	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
495	CD	495	495	495	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
1441	CD	1441	1441	1441	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
or	CC	or	or	or	N	O
depressed	VBN	depressed	depressed	depress	N	B-AdverseReaction
mood	NN	mood	mood	mood	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
treated	VBN	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
495	CD	495	495	495	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Depression	NN	depression	depression	depress	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
1441	CD	1441	1441	1441	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
495	CD	495	495	495	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Instances	NNS	instances	instance	instanc	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
ideation	NN	ideation	ideation	ideat	N	I-AdverseReaction
and	CC	and	and	and	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
1441	CD	1441	1441	1441	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
treated	VBN	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
495	CD	495	495	495	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	RB	placebo	placebo	placebo	N	O
committed	VBN	committed	committed	commit	N	O
suicide	NN	suicide	suicide	suicid	Y	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
none	NN	none	none	none	N	B-Negation
in	IN	in	in	in	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

Psoriasis	NN	psoriasis	psoriasis	psoriasi	Y	O
:	:	:	:	:	N	O
During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
0	CD	0	0	0	N	O
to	TO	to	to	to	N	O
16	CD	16	16	16	N	O
week	NN	week	week	week	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
920	CD	920	920	920	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
reported	VBD	reported	reported	report	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
506	CD	506	506	506	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
1308	CD	1308	1308	1308	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
depression	VB	depression	depression	depress	Y	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
506	CD	506	506	506	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Depression	NN	depression	depression	depress	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
1308	CD	1308	1308	1308	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
506	CD	506	506	506	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Instances	NNS	instances	instance	instanc	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
1308	CD	1308	1308	1308	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
506	CD	506	506	506	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
subject	NN	subject	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
attempted	VBD	attempted	attempted	attempt	N	B-AdverseReaction
suicide	RB	suicide	suicide	suicid	Y	I-AdverseReaction
while	IN	while	while	while	N	O
one	CD	one	one	one	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	RB	placebo	placebo	placebo	N	B-Factor
committed	VBN	committed	committed	commit	N	O
suicide	NN	suicide	suicide	suicid	Y	B-AdverseReaction
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Weight	NNP	weight	weight	weight	Y	O
Decrease	NNP	decrease	decrease	decreas	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
psoriatic	JJ	psoriatic	psoriatic	psoriat	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
(	(	(	(	(	N	O
PsA	NNP	psa	psa	psa	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
weight	VBD	weight	weight	weight	Y	B-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
between	IN	between	between	between	N	O
5%	CD	5%	5%	5%	N	O
-	:	-	-	-	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
body	NN	body	body	bodi	N	O
weight	NN	weight	weight	weight	Y	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
(	(	(	(	(	N	O
49	CD	49	49	49	N	O
497	CD	497	497	497	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
3.3%	CD	3.3%	3.3%	3.3%	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
495	CD	495	495	495	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
psoriasis	NN	psoriasis	psoriasis	psoriasi	Y	O
,	,	,	,	,	N	O
weight	VBD	weight	weight	weight	Y	B-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
between	IN	between	between	between	N	B-Severity
5%	CD	5%	5%	5%	N	I-Severity
-	:	-	-	-	N	I-Severity
10%	CD	10%	10%	10%	N	I-Severity
of	IN	of	of	of	N	I-Severity
body	NN	body	body	bodi	N	I-Severity
weight	NN	weight	weight	weight	Y	I-Severity
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
12%	CD	12%	12%	12%	N	O
(	(	(	(	(	N	O
96	CD	96	96	96	N	O
784	CD	784	784	784	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
19	CD	19	19	19	N	O
382	CD	382	382	382	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	B-Severity
of	IN	of	of	of	N	I-Severity
body	NN	body	body	bodi	N	I-Severity
weight	NN	weight	weight	weight	Y	I-Severity
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
784	CD	784	784	784	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
382	CD	382	382	382	N	O
)	)	)	)	)	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
their	PRP$	their	their	their	N	O
weight	NN	weight	weight	weight	Y	O
monitored	VBD	monitored	monitored	monitor	N	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
unexplained	VBN	unexplained	unexplained	unexplain	N	O
or	CC	or	or	or	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
weight	JJ	weight	weight	weight	Y	O
loss	NN	loss	loss	loss	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
weight	JJ	weight	weight	weight	Y	O
loss	NN	loss	loss	loss	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNS	interactions	interaction	interact	N	O

Co	NNP	co	co	co	N	O
-	:	-	-	-	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
strong	JJ	strong	strong	strong	N	O
cytochrome	NN	cytochrome	cytochrome	cytochrom	N	O
P450	NNP	p450	p450	p450	N	O
enzyme	NN	enzyme	enzyme	enzym	N	O
inducer	NN	inducer	inducer	induc	N	O
,	,	,	,	,	N	O
rifampin	NN	rifampin	rifampin	rifampin	N	O
,	,	,	,	,	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
reduction	NN	reduction	reduction	reduct	N	O
of	IN	of	of	of	N	O
systemic	JJ	systemic	systemic	system	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
apremilast	NN	apremilast	apremilast	apremilast	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
cytochrome	NN	cytochrome	cytochrome	cytochrom	N	O
P450	NNP	p450	p450	p450	N	O
enzyme	NN	enzyme	enzyme	enzym	N	O
inducers	NNS	inducers	inducer	induc	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
rifampin	NN	rifampin	rifampin	rifampin	N	O
,	,	,	,	,	N	O
phenobarbital	NN	phenobarbital	phenobarbital	phenobarbit	N	O
,	,	,	,	,	N	O
carbamazepine	NN	carbamazepine	carbamazepine	carbamazepin	N	O
,	,	,	,	,	N	O
phenytoin	NN	phenytoin	phenytoin	phenytoin	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
OTEZLA	NNP	otezla	otezla	otezla	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	JJ	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

